Firm has largely completed its portfolio trimming and restructuring and continues to see productivity gains, but organic growth fell short of many investors' expectations in fiscal 2015, inching up 1% for the year. During a fiscal 2015 full-year earnings call July 30, analysts questioned P&G's strategy, expected timing for improvements and whether recent divestitures will have the impact the firm foresees.
Procter & Gamble Co.'s fourth-quarter and full-year results for fiscal 2015 disappointed investors, with some suggesting that further divestitures, beyond beauty, may be warranted, if not more dramatic restructuring to right-size the company for improved top-line growth.
Others remain optimistic about P&G's longer-term prospects as the company realizes streamlining efficiencies and invests in innovation and emerging
US FDA Commissioner Martin Makary’s disavowal of a proposed reorganization plan may be an important turning point in the Trump Administration. The move does not improve the situation, but may mean the administration stops actively making things worse.
C&D reports Q1 net sales dropped 2.4% to $1.48bn, below its guidance for around 1% growth. Its brands’ sales at retail and market share grew in the quarter, but “experienced slowing category growth in the US market” as retailers reduced inventory levels.
Herbalife expects little impact from increased tariffs on imports from China but strong boosts from acquiring Pro2col Health and Pruvit Ventures Inc. and 51% ownership of Link BioSciences.
